Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

NGS may ID SCLC candidates for immunotherapy

SITC 2018

Key clinical point: Next-generation sequencing may help identify small cell lung cancer patients who will benefit from immunotherapy.

Major finding: Median progression-free survival and overall survival were significantly better among tumor mutational burden–high versus tumor mutational burden–low patients (3.3 vs. 1.2 months; hazard ratio, 0.37; and 10.4 vs. 2.5 months; HR, 0.38, respectively).

Study details: A series of 113 patients.

Disclosures: Dr. Ricciuti reported having no disclosures.

Read the article here.


SITC 2018